[go: up one dir, main page]

DK2368887T3 - 1, 2, 3-triazolderivater til anvendelse som stearoyl-coa desaturase-inhibitorer - Google Patents

1, 2, 3-triazolderivater til anvendelse som stearoyl-coa desaturase-inhibitorer

Info

Publication number
DK2368887T3
DK2368887T3 DK11168642.4T DK11168642T DK2368887T3 DK 2368887 T3 DK2368887 T3 DK 2368887T3 DK 11168642 T DK11168642 T DK 11168642T DK 2368887 T3 DK2368887 T3 DK 2368887T3
Authority
DK
Denmark
Prior art keywords
stearoyl
coa desaturase
desaturase inhibitors
triazold
derivatives
Prior art date
Application number
DK11168642.4T
Other languages
English (en)
Inventor
Anne Marie Jeanne Bouillot
Alain Laroze
Lionel Trottet
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Application granted granted Critical
Publication of DK2368887T3 publication Critical patent/DK2368887T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
DK11168642.4T 2007-11-09 2008-11-07 1, 2, 3-triazolderivater til anvendelse som stearoyl-coa desaturase-inhibitorer DK2368887T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0722077.5A GB0722077D0 (en) 2007-11-09 2007-11-09 Compounds
EP08846247A EP2207770B1 (en) 2007-11-09 2008-11-07 1, 2, 3-triazole derivatives for use as stearoyl-coa desaturase inhibitors

Publications (1)

Publication Number Publication Date
DK2368887T3 true DK2368887T3 (da) 2014-04-14

Family

ID=38858481

Family Applications (2)

Application Number Title Priority Date Filing Date
DK11168642.4T DK2368887T3 (da) 2007-11-09 2008-11-07 1, 2, 3-triazolderivater til anvendelse som stearoyl-coa desaturase-inhibitorer
DK08846247.8T DK2207770T3 (da) 2007-11-09 2008-11-07 1, 2, 3-triazolderivater til anvendelse som stearoyl-coa desaturase-inhibitorer

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK08846247.8T DK2207770T3 (da) 2007-11-09 2008-11-07 1, 2, 3-triazolderivater til anvendelse som stearoyl-coa desaturase-inhibitorer

Country Status (31)

Country Link
US (2) US8486977B2 (da)
EP (2) EP2207770B1 (da)
JP (1) JP5491407B2 (da)
KR (1) KR101577080B1 (da)
CN (1) CN101918376B (da)
AT (1) ATE512140T1 (da)
AU (1) AU2008324172B2 (da)
BR (1) BRPI0820471A2 (da)
CA (1) CA2705113C (da)
CO (1) CO6270331A2 (da)
CR (1) CR11482A (da)
CY (2) CY1112233T1 (da)
DK (2) DK2368887T3 (da)
DO (1) DOP2010000137A (da)
EA (1) EA016621B1 (da)
ES (2) ES2366422T3 (da)
GB (1) GB0722077D0 (da)
HR (2) HRP20110552T1 (da)
IL (1) IL205152A (da)
MA (1) MA31801B1 (da)
ME (1) ME01962B (da)
MX (1) MX2010005187A (da)
MY (1) MY163126A (da)
NZ (1) NZ584725A (da)
PL (2) PL2207770T3 (da)
PT (2) PT2207770E (da)
RS (2) RS53294B (da)
SI (2) SI2368887T1 (da)
UA (1) UA107324C2 (da)
WO (1) WO2009060053A1 (da)
ZA (1) ZA201002596B (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0722075D0 (en) * 2007-11-09 2007-12-19 Smithkline Beecham Corp Compounds
GB0722077D0 (en) * 2007-11-09 2007-12-19 Smithkline Beecham Corp Compounds
WO2010030046A1 (en) * 2008-09-15 2010-03-18 Daikin Industries, Ltd. Aqueous polymer dispersion composition and surface treatment agent
UA107917C2 (ru) * 2008-10-21 2015-03-10 Сімабей Терапьютікс, Інк. Арильный агонист рецептора gpr120 и его применение
FR2974089B1 (fr) * 2011-04-18 2014-04-25 Univ Nice Sophia Antipolis Derives de l'acadesine, produits et compositions les comprenant, leurs utilisations therapeutiques et leurs procedes de synthese.
US9233102B2 (en) 2012-03-07 2016-01-12 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
JP6027244B2 (ja) * 2012-09-17 2016-11-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ トリアゾールカルボキサミド誘導体
IL227890A0 (en) * 2013-08-08 2014-01-30 Galderm Therapeutics Ltd Antiaging compounds containing bile acid and fatty acid conjugates
EP3808349B1 (en) 2014-08-07 2022-10-05 Mayo Foundation for Medical Education and Research Compounds and methods for treating cancer
HUE058156T2 (hu) * 2015-01-30 2022-07-28 Neurocrine Biosciences Inc Helyettesített triazolok és ezekkel kapcsolatos eljárások
KR20180036318A (ko) * 2016-09-30 2018-04-09 경북대학교 산학협력단 2-아미노-2-(1-도데실-1h-1,2,3-트리아졸-4-일)프로판-1,3-디올 유도체를 유효성분으로 포함하는 퇴행성 신경질환 및 우울증 예방 또는 치료용 약학적 조성물
US11970486B2 (en) 2016-10-24 2024-04-30 Janssen Pharmaceutica Nv Compounds and uses thereof
AU2018205275B2 (en) * 2017-01-06 2024-05-02 Janssen Pharmaceutica Nv Methods for the treatment of neurological disorders
KR102292989B1 (ko) * 2017-03-29 2021-08-26 재단법인 아산사회복지재단 S1pr4를 타겟으로 하는 비알코올성 지방간염 예방 또는 치료용 조성물
US11873298B2 (en) 2017-10-24 2024-01-16 Janssen Pharmaceutica Nv Compounds and uses thereof
AU2019238326B2 (en) 2018-03-23 2025-03-06 Janssen Pharmaceutica Nv Compounds and uses thereof
EP3784234A1 (en) * 2018-04-25 2021-03-03 Yumanity Therapeutics, Inc. Compounds and uses thereof
KR102017324B1 (ko) * 2018-04-30 2019-09-02 경북대학교 산학협력단 신규한 asm 활성 직접 억제 화합물 2-아미노-2-(1,2,3-트리아졸-4-일)프로판-1,3-디올 유도체 및 이의 용도
KR20220007845A (ko) 2019-01-24 2022-01-19 유마니티 테라퓨틱스, 인크. 화합물 및 이의 용도
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
CN114656414B (zh) * 2022-05-24 2022-08-23 常熟华虞环境科技有限公司 三氮唑改性二氧化钛光催化剂及其制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722941A (en) 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
US4460372A (en) 1981-02-17 1984-07-17 Alza Corporation Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer
US4573996A (en) 1984-01-03 1986-03-04 Jonergin, Inc. Device for the administration of an active agent to the skin or mucosa
US4624665A (en) 1984-10-01 1986-11-25 Biotek, Inc. Method of transdermal drug delivery
US5223261A (en) 1988-02-26 1993-06-29 Riker Laboratories, Inc. Transdermal estradiol delivery system
US20070087363A1 (en) 1998-12-22 2007-04-19 Myriad Genetics, Incorporated Therapeutic methods, compounds and compositions
ATE475718T1 (de) 2000-02-24 2010-08-15 Xenon Pharmaceuticals Inc Stearoyl-coa-desaturase zur identifizierung von triglyceridreduktionstherapeutika
CA2430987A1 (en) 2000-09-26 2002-04-04 Xenon Genetics, Inc. Methods and compositions employing a novel stearoyl-coa desaturase-hscd5
MXPA04010622A (es) * 2002-04-26 2005-01-25 Lilly Co Eli Derivados de triazol como antagonistas de receptor de taquicinina.
US20060160794A1 (en) * 2003-06-12 2006-07-20 Amegadzie Albert K Tachykinin receptor antagonists
ES2386353T3 (es) 2003-07-30 2012-08-17 Xenon Pharmaceuticals Inc. Derivados de piridazina y su uso como agentes terapéuticos
CN101693697A (zh) * 2003-07-30 2010-04-14 泽农医药公司 哌嗪衍生物和它们作为治疗剂的用途
WO2007046868A2 (en) 2005-05-19 2007-04-26 Xenon Pharmaceuticals Inc. Thiazolidine derivatives and their uses as therapeutic agents
WO2007046867A2 (en) 2005-05-19 2007-04-26 Xenon Pharmaceuticals Inc. Piperidine derivatives and their uses as therapeutic agents
WO2008073461A2 (en) 2006-12-11 2008-06-19 Wyeth Ion channel modulators
GB0625654D0 (en) * 2006-12-21 2007-01-31 Smithkline Beecham Corp Compounds
GB0625605D0 (en) * 2006-12-21 2007-01-31 Smithkline Beecham Corp Compounds
GB0625604D0 (en) * 2006-12-21 2007-01-31 Smithkline Beecham Corp Compounds
JP2010520162A (ja) * 2007-02-28 2010-06-10 スミスクライン ビーチャム コーポレーション ステアロイル−ＣｏＡデサチュラーゼ阻害剤であるチアジアゾール誘導体
WO2008138917A1 (en) * 2007-05-15 2008-11-20 Neurosearch A/S Novel aromatic heterocyclic carboxylic acid amide derivatives useful as potassium channel modulators
GB0714129D0 (en) 2007-07-19 2007-08-29 Smithkline Beecham Corp compounds
GB0715055D0 (en) 2007-08-02 2007-09-12 Smithkline Beecham Corp Compounds
GB0721419D0 (en) 2007-10-31 2007-12-12 Smithkline Beecham Corp Compounds
GB0722075D0 (en) * 2007-11-09 2007-12-19 Smithkline Beecham Corp Compounds
GB0722077D0 (en) * 2007-11-09 2007-12-19 Smithkline Beecham Corp Compounds
GB0810913D0 (en) 2008-06-13 2008-07-23 Smithkline Beecham Corp Comppounds

Also Published As

Publication number Publication date
CN101918376B (zh) 2013-11-06
MA31801B1 (fr) 2010-10-01
ZA201002596B (en) 2010-12-29
EP2207770A1 (en) 2010-07-21
US8486977B2 (en) 2013-07-16
MX2010005187A (es) 2010-05-27
GB0722077D0 (en) 2007-12-19
HRP20110552T1 (hr) 2011-09-30
AU2008324172B2 (en) 2012-03-15
ES2366422T3 (es) 2011-10-20
IL205152A0 (en) 2010-11-30
RS51918B (sr) 2012-02-29
DK2207770T3 (da) 2011-09-12
HK1160467A1 (en) 2012-08-17
CY1112233T1 (el) 2015-12-09
KR101577080B1 (ko) 2015-12-11
CN101918376A (zh) 2010-12-15
BRPI0820471A2 (pt) 2015-06-16
CA2705113A1 (en) 2009-05-14
CA2705113C (en) 2016-01-05
EA201070588A1 (ru) 2010-10-29
WO2009060053A1 (en) 2009-05-14
CY1115058T1 (el) 2016-12-14
CR11482A (es) 2010-07-09
RS53294B (sr) 2014-08-29
CO6270331A2 (es) 2011-04-20
MY163126A (en) 2017-08-15
AU2008324172A1 (en) 2009-05-14
US20130281499A1 (en) 2013-10-24
ATE512140T1 (de) 2011-06-15
HRP20140346T1 (hr) 2014-05-09
US20100297054A1 (en) 2010-11-25
ES2457521T3 (es) 2014-04-28
US9051281B2 (en) 2015-06-09
PL2368887T3 (pl) 2014-07-31
JP5491407B2 (ja) 2014-05-14
PT2368887E (pt) 2014-05-15
HK1141528A1 (en) 2010-11-12
EP2368887A1 (en) 2011-09-28
IL205152A (en) 2013-10-31
JP2011503031A (ja) 2011-01-27
DOP2010000137A (es) 2010-08-15
SI2368887T1 (sl) 2014-05-30
NZ584725A (en) 2012-05-25
ME01962B (en) 2012-02-29
PL2207770T3 (pl) 2011-10-31
EA016621B1 (ru) 2012-06-29
EP2368887B1 (en) 2014-02-26
PT2207770E (pt) 2011-09-01
EP2368887B8 (en) 2014-04-16
KR20100095574A (ko) 2010-08-31
SI2207770T1 (sl) 2011-09-30
UA107324C2 (uk) 2014-12-25
EP2207770B1 (en) 2011-06-08

Similar Documents

Publication Publication Date Title
DK2368887T3 (da) 1, 2, 3-triazolderivater til anvendelse som stearoyl-coa desaturase-inhibitorer
WO2008074824A3 (en) Isoquinolinecarboxamides as inhibitors of stearoyl-coa desaturase (scd)
WO2008074834A3 (en) Isoquinolinecarboxamides as inhibitors of stearoyl-coa desaturase (scd)
WO2008074832A3 (en) Isoquinolinecarboxamides as inhibitors of stearoyl-coa desaturase ( scd)
DE602007004618D1 (de) Pyridin- und pyrazinderivate als mnk-kinaseinhibitoren
CY1112831T1 (el) Παραγωγα αζαβιρηενυlαμινοβενζοιc acid σαν παραγοντες καταστολης dhodh
UA99617C2 (ru) Производные пирролконденсированного азотсодержащего гетероцикла, их получение и фармацевтическое применение
NO20076197L (no) Nye 2-azetidinonderivater anvendbare i behandling av hyperlipidemiske tilstander
EA200802329A1 (ru) Производные триазола ii
MA32150B1 (fr) Inhibiteurs heterocycliques de la stearoyl-coa desaturase
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
MX2010006108A (es) Inhibidores de estearoil-coa-desaturasa.
MX2009013501A (es) Compuestos piperidinicos y sus usos.
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
WO2008074833A3 (en) Compounds
EA200900631A1 (ru) Замещённые пиразолы и триазолы, как ингибиторы кбв (кинезин-белок веретена)
MX2007004248A (es) Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa.
TW200626158A (en) Naphthaline derivatives
UA106200C2 (uk) Заміщені похідні оксіндолу та їхнє застосування для лікування захворювань, залежних від вазопресину
UY32316A (es) Derivados de piperidina utiles en el tratamiento de infecciones bacterianas
NO20073702L (no) Ikke-steroid glukocorticoid reseptor modulatorer
MX2009005242A (es) Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo.
NO20083352L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
EA201000882A1 (ru) Соединение, его применение и фармацевтическая композиция, содержащая это соединение
UA87327C2 (ru) Производные бензимидазола, композиция, которая их содержит, их получение и применение